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of novel drugs to patients and fosters divergence in reimbursement status. The 
objectives were to identify differences in REA by EU-HTA agencies, discuss the 
impact of this variation on time to patient access and assess the potential benefits 
of a centralized REA. Methods: Differences in clinical assessment across EU-HTA 
bodies were analysed for selected EMA approved Novartis drugs (internal data and 
structured telephonic interviews with Novartis Country Pharma Organisations 
(CPOs) and drugs marketed by other companies (literature review). Results: 
Differences in acceptance of comparators, subgroups and end-points were seen 
in REA across countries. Although fingolimod, secured wide reimbursement in EU 
for Relapsing-Remitting Multiple Sclerosis (RRMS), HTA bodies differed in their 
end-points’ acceptance. Example, UK accepted annual relapse rate, disability pro-
gression and MRI-lesions, while Germany didn’t accept the latter as end-point. 
Variations were seen in countries’ requirements for additional analysis to support 
REA. Example, Germany granted a ‘small additional benefit’ rating for Rapidly 
Evolving Severe RRMS subgroup based on indirect comparison, while, even an 
additional mixed treatment comparison couldn’t support REA for this subgroup in 
UK. Amongst non-Novartis drugs; pertuzumab review by IQWIG and GBA resulted 
in different end-point acceptance, with negative and restricted access recom-
mendation, respectively. For sofosbuvir, HTA bodies differed from EMA label and 
saw clinical value only in some patient subgroups. Example, IQWIG recommended 
the drug for only HCV genotype-2 whereas ZIN (Netherlands) recommended it for 
genotype-1 and 4. CPOs’ survey indicated that centralized EU-REA could reduce 
time to patient access (by ~3-4 months), through avoiding repetitive clinical 
evaluation and saving time on pricing/reimbursement pathway. ConClusions: 
Harmonized REA has the potential to reduce delay in patient access, strengthen 
the equity of care and increase predictability of expectations from pharmaceutical 
companies’ research programs.
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ExtErnal rEfErEncE Pricing from tHE PErsPEctivE of slovEnia
Mardetko N, Kos M
University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia
objeCtives: We aimed to present the characteristics and challenges of the external 
reference pricing (ERP) from the perspective of Slovenia. Methods: The literature 
search was made for the information on ERP in countries included in the Slovenian 
country basket and countries that refer Slovenia. The data on characteristics of the 
ERP such as country basket composition, calculation of the reference price, scope 
of medicines, type of comparable price and use of the ERP as main or supportive 
criterion were taken into account. Results: Slovenia defines medicine prices based 
on the prices in Austria, Germany and France, while 17 countries refer Slovenia. 
Slovenia’s greatest potential impact concerns the medicine prices in Croatia, Bosnia, 
Serbia and Portugal that refer only three countries. Their calculation method is an 
average price of reference countries, indicating that the role of Slovenia is not as 
large as it could be if the calculation method was the lowest price or the average of 
lowest three prices in reference countries. However, Slovenia does not have a greater 
role in countries calculating reference price as the lowest price or the average of 
the three lowest prices, while most of those countries refer 20 or more countries 
and Slovenia is not necessary the country with the lowest medicine price. The 
ERP represents a special challenge for countries as Slovenia that do not represent 
a large medicines market and try to reduce medicine costs to a greater extent 
than others with potential risk of medicines withdrawal. Slovenia does not have 
a direct impact on medicine prices in countries using ERP as supportive criterion. 
Further, Slovenia and Austria refer each other, representing an overlapping connec-
tion. ConClusions: The small pharmaceutical market and potentially large impact 
on the prices of medicines in other countries places Slovenia in a special position.
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objeCtives: This study appraised the health professionals and managers’ value 
judgments in Brazilian HTA process, through a new method of research that 
addresses clinical scenarios to simulate real world dilemmas and support budget 
allocation. The decisions should be made under clinical and epidemiological aspects, 
and, also, economic, social, ethical and cultural factors. The main objective was to 
evaluate how these factors have influenced the decision makers in HTA resources 
allocation. We agreed to call this model by Decision Making Clinical Scenarios 
(DMCS). Methods: This study was conducted through a decision making ques-
tionnaire with four clinical scenarios involving HTA. These scenarios introduced 
issues involving value judgments, preferences and structuring choices, considering 
a severe budget restraint. The presented trade-offs were related to health policies, 
such as budget impact, sources of funding, eligible patients, technology charac-
teristics and disease epidemiology. Results: The results showed a conservative 
trend. In all three scenarios involving some form of technological incorporation, the 
most chosen option was to avoid incorporation. Alternatives of funding, as reduc-
tion/extinction of current healthcare programs and creation of a new tax, were not 
accepted as solutions. In budget allocation between prevention and treatment pro-
grams, respondents were suited to a preventive long-term strategy. ConClusions: 
The scenarios have been shown understandable. The absolute scarcity of resources 
clearly influenced the results. In search of a paradigm for decision making, most of 
respondents prioritized to save resources, instead of incorporating the technologies. 
We concluded that managers are not guided only by clinical benefit of a decision. 
They valorized the importance of funding mechanisms and budget control that 
enable incorporation, considering economic, social, ethical, and structural aspects. 
This study model seems to be useful to evaluate the trends of conduct of decision 
makers. This model can be used in further researches, bringing different factors and 
criteria into discussion, through clinical real world situations.
tion (n= 7 drugs). For each claim the source of payment and price difference, where 
applicable, were deduced from the recorded expenditure. Trends, including costs to 
the HSE, were monitored over time. The impact of time since policy introduction and 
price difference magnitude on DNS likelihood (HSE payment) were explored using 
logistic regression. Results: Overall, generic drug dispensing rose from 79% to 92% at 
six months following policy introduction. However, within premium-priced products 
dispensed (8% overall), the proportion of DNS increased from 15% to 39%. Time since 
policy introduction and magnitude of price difference were both positive predic-
tors of DNS (versus patient payment) (p< 0.001). ConClusions: GS/RP successfully 
increased generic dispensing. However, estimated DNS rates increased significantly in 
the first 6 months, incurring additional costs to the HSE, and were predicted by higher 
potential costs to the patient. These trends suggest that the burden of co-payment 
within GS/RP is increasingly being passed to the health service. With continual roll-
out of GS/RP, interventions may be required to ensure DNS occurrences appropriately 
reflect medical need.
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objeCtives: The appropriate use of drugs including antibiotics is crucial towards 
achieving better quality of life. The aim of this study was to assess the prescrib-
ing practices and antibiotic use patterns in the Accident and Emergency (A&E) 
Department of the Bahawal Victoria Hospital (BVH), Bahawalpur, Pakistan. Methods: 
A descriptive, non-experimental, retrospective and cross sectional study design was 
employed. A sample of 4,320 prescriptions (systematic random sampling) was drawn 
out of the total prescriptions written during January to December 2014. The standard 
World Health Organization/International Network for Rational Use of Drugs (WHO/
INRUD) prescribing indicators were used to enumerate prescribing practices of the 
physicians. Published ideal standards for each of the indicators were used to identify 
the irrational drug use. An additional indicator (the percentage share of each anti-
biotic) was also determined. Results: The average number of drugs per encounter 
was 2.3 (SD = 1.3) (optimal value = 1.6–1.8), the drugs prescribed by generic name 
were 83.1% (optimal value = 100%), the encounters with an antibiotic and injec-
tion prescribed were 52.4% (optimal value = 20.0–26.8%) and 98.0% (optimal value 
= 13.4–24.1%) respectively and the drugs prescribed from Essential Drugs List were 
81.5% (optimal value = 100%). Out of 52.4% (n = 2,262) prescriptions with antibiotics 
prescribed, 77.7% (n = 1758) had one antibiotic, 22.1% (n = 499) included two antibi-
otics, and only 0.2% (n = 5) had three antibiotics. Cephalosporins (81.5%), were the 
most commonly prescribed class of antibiotics followed by penicillins (6.4%) and 
fluoroquinolones (6.2%). Among the individual antibiotics, Ceftriaxone contributed 
the highest percentage share of 71.8% followed by cefotaxime (5.6%) and metronida-
zole (4.7%). The most frequently prescribed antibiotic combination was ciprofloxacin 
with metronidazole (52.1%). ConClusions: The irrational prescribing practices were 
common. Continuous education and training of the physicians is required to ensure 
rational prescribing of antibiotics and injections.
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HoW to nEgotiatE Pricing
Hill CA, Harries M
MAP BioPharma Limited, Cambridge, UK
objeCtives: The UK operates free pricing of new chemical entities (NCEs). The 
2014 PPRS was a radical departure from its predecessors, focussing on industry’s 
obligation to repay the Department of Health (DH) for growth in the NHS drug 
expenditure beyond certain limits. These repayments look set to exceed original 
estimates, reducing certainty for members of the voluntary scheme. The statutory 
regulations impose higher price cuts at the outset, ensuring those not in the PPRS 
do not have an advantage. As NHS sales from new NCEs launched after Jan 1st 2014 
are exempt from PPRS payment calculations, we show that the scheme favours 
those with products early in their life span. Methods: 15 case studies of small 
(n= 5), medium (n= 6) and large companies (n= 4) were reviewed to identify the 
implications for manufacturers with established portfolios compared to those with 
new launches after January 2014 under the PPRS and statutory scheme. We review 
legal options for companies who consider themselves unfairly treated. Results: 
Evidence exists of an imbalance in the PPRS impact, thus negatively affecting the 
UK as an early launch market. Companies have successfully challenged the appli-
cation of the statutory scheme price reductions to products already covered by a 
tender and the impact on international reference pricing. The scheme potentially 
amounts to an unlimited payment to the DH and worryingly payments are allo-
cated to an undefined pot rather than to the original budget holder. Price rises are 
possible, subject to justification on the basis of eight main factors. ConClusions: 
Companies supplying mainly mature products that offer the NHS good value for 
money are disproportionately affected compared with larger companies with a 
broader international portfolio, leading to an increase in price rise applications. 
Companies with a pipeline of NCEs, which are commonly more expensive, are the 
winners despite driving greater NHS expenditure.
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objeCtives: Heterogeneity in interpreting same clinical data of EMA approved 
medicines by HTA agencies of EU member states potentially delays accessibility 
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current regulation and practices; (4) Lack of an ICER threshold. The likely future of 
health economic assessment of drugs in France will imply the expansion of health 
economic assessment scope, the implementation of an impactful ICER threshold, 
the generalisability of coverage with evidence, and eventually the possible merge 
of the CEESP and the CT. ConClusions: Major steps in French HTA are expected 
to occur in the near future. Empowerment of the CEESP (merged or not with the 
CT) is expected, and it may become the unique or leading committee addressing 
the HTA of pharmaceuticals in France. However, it is likely that the robust and well-
established methodology developed by the CT (SMR, ASMR) to assess comparative 
efficacy or effectiveness will remain in force.
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arE tHE irisH sloWEr tHan tHEy tHink? a systEmatic analysis of all 
rEcEnt ncPE aPPraisals
Macaulay R, Tan H
PAREXEL, London, UK
objeCtives: The National Centre for Pharmacoeconomics (NCPE) reviews the 
cost effectiveness of new medicines following an application for reimbursement 
in Ireland. All medicines are subjected to a preliminary rapid review (RR, stated 
to take ~2 weeks) with only high cost products and those with significant budget 
impact subjected to formal pharmacoeconomic assessments (PEA, stated to be com-
pleted in < 3 months). This research aims to review all recent NCPE appraisals to 
determine what proportion of drugs require a full appraisal, the review times and 
rates of approvals. Methods: Publically available decision summaries from the 
NCPE were identified (from 1st January 2013 to 31st May 2015) and the outcome, 
date, indication, and whether a full PEA was needed were extracted. Results: 110 
appraisals were identified with 43% (47/110) approved following RR. Of these, only 
21% (10/47) were reviewed within < 2 weeks; the rest taking on average > 2x longer 
than stated (29 days). Of the 57% (63/111) appraisals deemed to require a full PEA, 
62% (39/63) were initiated, on average, > 5 months post-RR. Only 33% (13/39) of full 
PEAs were eventually recommended, adding another 5 months (average 152 days) 
to the process. 27% (30/110) appraisals were for oncology medicines; 90% (27/30) of 
which required a full PEA. Only 15 were NCPE-appraised, almost all of which were 
not recommended (87%, 13/15). ConClusions: The total average length of time 
between start of the RR to final PEA recommendation is up to a year (12 months), 
which is substantially longer than what is claimed. If companies can convince the 
NCPE that their medicine is not high cost, nor has a significant budget impact, the 
RR process can enable rapid reimbursement within 1-2 months. However, if a full 
PEA is required, this significantly delays reimbursement decisions, with positive 
recommendations being difficult to achieve, especially for oncology medicines.
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objeCtives: The Swedish Dental and Pharmaceutical Benefits Agency (TLV) make 
recommendations on whether outpatient prescription drugs should be publically 
reimbursed with cost-effectiveness being a key criterion. By contrast, no national 
economic assessment was traditionally implemented for hospital pharmaceuticals, 
which were typically individually appraised by each county council. However, since 
January 2011, a national co-ordinating group of Swedish county councils (NLT) can 
request that selected in-patient therapies undergo a health economic assessment 
by the TLV, on which the NLT can conduct price negotiations and issue a national 
recommendation. This research aims to evaluate which drugs the NLT have been 
appraising and what the final outcomes were. Methods: A systematic search for all 
publically available NLT recommendation documents up to 1stMay 2015 was under-
taken and the drug, date, indication and recommendation, was extracted. Results: 
50 appraisal documents were identified, 54% (27/50) of which were recommended, 
16% (8/50) received restricted recommendations, 16% (8/50) rejected and 14% (7/50) 
classified as other (deferred/unclear). However, it is important to note that many of 
the drugs that were approved were not recommended at list price with 41% (11/27) of 
recommendations being conditional on or following a discount (including confidential 
discounts) and 11% (3/27) being based on an agreed risk sharing agreement. 2 apprais-
als were for ZOSTAVAX in shingles, which was previously reimbursed but, based on 
more recent data, was now deemed to no longer offer benefits that justified its costs. 
44% (22/50) appraisals were for oncology drugs only 1 (2%) of which was rejected 
(YERVOY, but was accepted upon resubmission). ConClusions: The NLT appears to 
have successfully implemented a process where significant price pressure is exerted 
on companies with discounts being frequently secured without being too restrictive 
over coverage. Could giving other cost-utility HTA bodies negotiating powers help 
bridge the gap between cost-containment and broadening coverage?
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closing tHE gaP bEtWEEn Hta anD innovation UPtakE in finnisH 
HosPitals
Pasternack I, Halmesmäki E, Roine RP
University of Helsinki and Helsinki University Hospital, Helsinki, Finland
objeCtives: Health technology assessment (HTA) is not deeply rooted in Finnish 
hospitals despite of long lasting attempts to introduce it into routine decision mak-
ing. Both the processes and content of the HTA approach have been challenged. 
The EU-funded AdHopHTA project has provided good practices and new tools for 
hospital based HTA. The aim of this study is to smoothen the introduction of these 
new tools by examining the obstacles HTA currently faces in hospitals. Methods: 
Semi-structured group interviews in five public hospitals and two health care cen-
tres. Interviewees were clinical unit managers, division managers, and financial 
or procurement managers. Questions were related to the process of proposing, 
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objeCtives: Chinese drug pricing reform initiated on 1stJune 2015 aims to create 
incentives for efficient management of drug reimbursement budget. This study aimed 
to assess the potential impact of the reform from the societal perspective. Methods: 
We conducted a thorough research on the drug pricing reform using three Chinese 
databases (CNKI, Wanfang, Weipu), Chinese health authorities’ websites, relevant 
press releases, pharmaceutical blogs and discussion forums. This research was com-
plemented with targeted interviews with Chinese key opinion leaders representing 
authorities’ and prescribers’ perspectives. Results: The reform may include intro-
duction of internal reference pricing (IRP) for drugs with the same active ingredient 
and dosage form. Therapeutic interchangeability of drugs is an important issue in 
China. Interviewed opinion leaders consistently agree that there are discrepancies 
in terms of quality between imported drugs and some locally produced generics. 
Introduction of IRP may promote the use of cheaper generics with questionable qual-
ity. Increased use of low-quality drugs may affect patients’ safety and treatment 
outcomes, and in turn lead to undesired increase of expenditures in other health-
care sectors. It could also increase inequity between different income groups if, as a 
result of increased co-payment, only the wealthiest could afford high-quality drugs. 
Additionally, the reform should not be implemented in isolation. Creating effective 
incentives for cost-containment without affecting healthcare quality requires global, 
rather than ‘micro-level’ focus. With hospitals being the main distributor of out-
patient drugs in China and economically depending on profit generated from drugs 
sales, pricing reform should be comprehensive and address restructuring of hospitals’ 
financing and management system. ConClusions: Before introducing the reform 
on a big scale, all local specificities and challenges should be properly addressed, e.g. 
the issue of poor-quality drugs. International reference pricing policies cannot be 
transferred to China without being adjusted for local context. To be successful, the 
reform requires a comprehensive approach.
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objeCtives: Since 2009, the Chinese government has launched a global healthcare 
reform program aiming to control healthcare expenditure and increase the quality of 
care. As a part of this program, a new drug pricing reform was initiated starting 1stJune 
2015. The objective of this study is to describe the changing landscape of drug pricing 
policy in China. Methods: We conducted a thorough research on drug pricing reform 
using three Chinese databases (CNKI, Wanfang, Weipu), Chinese health authorities’ 
websites, relevant press releases, pharmaceutical blogs and discussion forums. The 
secondary research was complemented with targeted interviews with Chinese key 
opinion leaders representing authorities’ and prescribers’ perspectives. Results: With 
the current reform, the government attempts to replace its direct control over prices 
of reimbursable drugs by an indirect influence. Government pricing and government 
guided pricing are abolished for most drugs giving manufacturers more freedom to set 
market prices. However, an introduction of a form of internal reference pricing (IRP), 
named ”reimbursement standard” has been announced. To inform the best approach 
for implementation of this reform, China is currently running pilot projects in several 
cities. Sanming is piloting a form of IRP for drugs with the same active ingredient and 
dosage form; it set the reference price at the price of the cheapest generic. Shaoxing and 
Anhui are testing the concept of “2nd price negotiation” allowing hospitals to directly 
negotiate discounts with manufacturers using provincial government procurement 
prices as reimbursement caps. First results of Sanming and Shaoxing pilots have 
already been reported, proving their potential for drug budget saving. ConClusions: 
Many elements of the reform remain unclear and will likely depend on pilot projects 
outcomes. It seems that the Chinese government is considering adaptation of IRP poli-
cies commonly used by European countries. However, foreign pricing policies cannot 
be transferred to China without being adjusted for local characteristics.
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objeCtives: The Economic and Public Health Assessment Committee (CEESP) was 
introduced in 2012 as a specialised committee affiliated with the ‘Haute Autorité 
de Santé’ (HAS) in charge of providing health economic opinions. This research 
provides a forward-looking analysis of health economic assessment of pharma-
ceuticals in France and its impact on market access of drugs. It also provides likely 
directions of the future French HTA organisation and processes. Methods: We 
conducted a grey literature search on the HAS website and decision makers’ public 
presentations and comments. This search was complemented with a meeting with 
experts in market access and health economics, HTA and public health to discuss 
the current functioning and the likely future path of health economic assessment 
in France. The main issues that emerged from the search and the discussion were 
consolidated and analysed. Results: Major sources of inefficiencies appeared fol-
lowing the introduction of health economic assessment: (1) Duplication of work 
between the CEESP and the CT; (2) Resolution of divergent opinions between the 
CEEPS and the CEPS; (3) Confusion and conflicting information with respect to the 
